(ALKS) Alkermes - Overview
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NASDAQ (USA) | Market Cap: 6.134m USD | Total Return: 39.5% in 12m
Avg Turnover: 81.1M
EPS Trend: 67.3%
Qual. Beats: 1
Rev. Trend: -31.0%
Qual. Beats: 1
Warnings
Earnings expected to drop: P/E 40.9 → Forward 97.1
Beneish M-Score -0.83 > -1.5 - likely earnings manipulation
Altman Z'' 0.72 < 1.0 - financial distress zone
Overextended 1w
Tailwinds
Supp Ema20, Idiosyncratic Leader, Confidence
Alkermes plc is a biopharmaceutical company specializing in treatments for central nervous system (CNS) disorders, including schizophrenia, bipolar I disorder, and substance use disorders. Its commercial portfolio features long-acting injectables and oral suspensions, such as ARISTADA and VIVITROL, designed to improve patient adherence in chronic therapeutic areas. The company operates within the biotechnology sector, where high research and development costs are often offset by patent-protected proprietary technology platforms and licensing agreements.
The business model relies on a combination of direct product sales and strategic collaborations with major industry players like Janssen Pharmaceutica. By leveraging its drug delivery technologies, the company develops extended-release formulations that extend product lifecycles and provide steady royalty streams. Investors can further evaluate these financial drivers and clinical milestones on ValueRay.
Founded in 1987 and headquartered in Dublin, Ireland, Alkermes maintains a global footprint with significant operations in the United States. Its pipeline continues to focus on neurological disorders, targeting unmet medical needs through both clinical-stage candidates and preclinical research.
- LYBALVI market share expansion drives long-term revenue growth in antipsychotic segment
- ARISTADA sales volume remains primary contributor to proprietary product revenue streams
- VIVITROL demand fluctuates based on public health policy and addiction treatment funding
- Royalties from Janssen collaboration provide high-margin cash flow for R&D investment
- Clinical trial results for neurological pipeline candidates dictate future valuation premiums
| Net Income: 152.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -17.92 > 1.0 |
| NWC/Revenue: 48.59% < 20% (prev 68.39%; Δ -19.80% < -1%) |
| CFO/TA 0.06 > 3% & CFO 256.2m > Net Income 152.7m |
| Net Debt (1.14b) to EBITDA (276.4m): 4.13 < 3 |
| Current Ratio: 2.27 > 1.5 & < 3 |
| Outstanding Shares: last quarter (166.2m) vs 12m ago -1.51% < -2% |
| Gross Margin: 86.63% > 18% (prev 0.84%; Δ 8.58k% > 0.5%) |
| Asset Turnover: 49.28% > 50% (prev 72.71%; Δ -23.42% > 0%) |
| Interest Coverage Ratio: 7.15 > 6 (EBITDA TTM 276.4m / Interest Expense TTM 33.2m) |
| A: 0.18 (Total Current Assets 1.36b - Total Current Liabilities 599.5m) / Total Assets 4.26b |
| B: -0.19 (Retained Earnings -801.3m / Total Assets 4.26b) |
| C: 0.07 (EBIT TTM 237.2m / Avg Total Assets 3.17b) |
| D: -0.32 (Book Value of Equity -802.3m / Total Liabilities 2.51b) |
| Altman-Z'' = 0.72 = B |
| DSRI: 1.23 (Receivables 407.6m/321.8m, Revenue 1.56b/1.51b) |
| GMI: 0.97 (GM 86.63% / 84.42%) |
| AQI: 4.44 (AQ_t 0.61 / AQ_t-1 0.14) |
| SGI: 1.03 (Revenue 1.56b / 1.51b) |
| TATA: -0.02 (NI 152.7m - CFO 256.2m) / TA 4.26b) |
| Beneish M = -0.83 (Cap -4..+1) = D |
As of May 30, 2026, the stock is trading at USD 42.19 with a total of 4,268,629 shares traded.
Over the past week, the price has changed by +14.18%,
over one month by +25.16%,
over three months by +40.17% and
over the past year by +39.47%.
Alkermes has received a consensus analysts rating of 4.13. Therefore, it is recommended to buy ALKS.
- StrongBuy: 8
- Buy: 1
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 45.4 | 7.7% |
P/E Trailing = 40.8889
P/E Forward = 97.0874
P/S = 3.9261
P/B = 3.5019
P/EG = 1.9605
Revenue TTM = 1.56b USD
EBIT TTM = 237.2m USD
EBITDA TTM = 276.4m USD
Long Term Debt = 1.48b USD (from longTermDebt, last quarter)
Short Term Debt = 34.1m USD (from shortTermDebt, last quarter)
Debt = 1.65b USD (from shortLongTermDebtTotal, last quarter) + Leases 71.3m
Net Debt = 1.14b USD (calculated: Debt 1.65b - CCE 511.9m)
Enterprise Value = 7.27b USD (6.13b + Debt 1.65b - CCE 511.9m)
Interest Coverage Ratio = 7.15 (Ebit TTM 237.2m / Interest Expense TTM 33.2m)
EV/FCF = 32.80x (Enterprise Value 7.27b / FCF TTM 221.8m)
FCF Yield = 3.05% (FCF TTM 221.8m / Enterprise Value 7.27b)
FCF Margin = 14.20% (FCF TTM 221.8m / Revenue TTM 1.56b)
Net Margin = 9.78% (Net Income TTM 152.7m / Revenue TTM 1.56b)
Gross Margin = 86.63% ((Revenue TTM 1.56b - Cost of Revenue TTM 208.8m) / Revenue TTM)
Gross Margin QoQ = 84.33% (prev 87.98%)
Tobins Q-Ratio = 1.71 (Enterprise Value 7.27b / Total Assets 4.26b)
Interest Expense / Debt = 2.01% (Interest Expense 33.2m / Debt 1.65b)
Taxrate = 17.08% (49.8m / 291.4m)
NOPAT = 196.7m (EBIT 237.2m * (1 - 17.08%))
Current Ratio = 2.27 (Total Current Assets 1.36b / Total Current Liabilities 599.5m)
Debt / Equity = 0.94 (Debt 1.65b / totalStockholderEquity, last quarter 1.75b)
Debt / EBITDA = 4.13 (Net Debt 1.14b / EBITDA 276.4m)
Debt / FCF = 5.14 (Net Debt 1.14b / FCF TTM 221.8m)
Total Stockholder Equity = 1.73b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.82% (Net Income 152.7m / Total Assets 4.26b)
RoE = 6.03% (Net Income TTM 152.7m / Total Stockholder Equity 2.53b)
RoCE = 5.90% (EBIT 237.2m / Capital Employed (Equity 2.53b + L.T.Debt 1.48b))
RoIC = 6.18% (NOPAT 196.7m / Invested Capital 3.18b)
WACC = 7.08% (E(6.13b)/V(7.79b) * Re(8.54%) + D(1.65b)/V(7.79b) * Rd(2.01%) * (1-Tc(0.17)))
Discount Rate = 8.54% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -37.78 | Cagr: -1.04%
[DCF] Terminal Value 73.10% ; FCFF base≈325.7m ; Y1≈285.6m ; Y5≈230.8m
[DCF] Fair Price = 15.38 (EV 3.70b - Net Debt 1.14b = Equity 2.56b / Shares 166.7m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 67.32 | EPS CAGR: 33.21% | SUE: 3.07 | # QB: 1
Revenue Correlation: -31.01 | Revenue CAGR: -1.67% | SUE: 1.27 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.33 | Chg30d=+557.60% | Revisions=N/A | Analysts=4
EPS next Quarter (2026-09-30): EPS=0.36 | Chg30d=N/A | Revisions=N/A | Analysts=4
EPS current Year (2026-12-31): EPS=1.43 | Chg30d=+2288.17% | Revisions=N/A | GrowthEPS=-31.7% | GrowthRev=+22.7%
EPS next Year (2027-12-31): EPS=2.35 | Chg30d=+236.41% | Revisions=+20% | GrowthEPS=+64.3% | GrowthRev=+4.2%
[Analyst] Revisions Ratio: +20%